Ceravolo Isabela P, Aguiar Anna C, Adebayo Joseph O, Krettli Antoniana U
Instituto René Rachou, Fundação Oswaldo Cruz (Fiocruz), Belo Horizonte, Brazil.
Departamento de Biociência, Universidade Federal de São Paulo, Santos, Brazil.
Front Pharmacol. 2021 Sep 22;12:734263. doi: 10.3389/fphar.2021.734263. eCollection 2021.
Malaria is an endemic disease that affected 229 million people and caused 409 thousand deaths, in 2019. Disease control is based on early diagnosis and specific treatment with antimalarial drugs since no effective vaccines are commercially available to prevent the disease. Drug chemotherapy has a strong historical link to the use of traditional plant infusions and other natural products in various cultures. The research based on such knowledge has yielded two drugs in medicine: the alkaloid quinine from Cinchona species, native in the Amazon highland rain forest in South America, and artemisinin from Artemisia annua, a species from the millenary Chinese medicine. The artemisinin-based combination therapies (ACTs), proven to be highly effective against malaria parasites, and considered as "the last bullet to fight drug-resistant malaria parasites," have limited use now due to the emergence of multidrug resistance. In addition, the limited number of therapeutic options makes urgent the development of new antimalarial drugs. This review focuses on the antimalarial activities of 90 plant species obtained from a search using Pubmed database with keywords "antimalarials," "plants" and "natural products." We selected only papers published in the last 10 years (2011-2020), with a further analysis of those which were tested experimentally in malaria infected mice. Most plant species studied were from the African continent, followed by Asia and South America; their antimalarial activities were evaluated against asexual blood parasites, and only one species was evaluated for transmission blocking activity. Only a few compounds isolated from these plants were active and had their mechanisms of action delineated, thereby limiting the contribution of these medicinal plants as sources of novel antimalarial pharmacophores, which are highly necessary for the development of effective drugs. Nevertheless, the search for bioactive compounds remains as a promising strategy for the development of new antimalarials and the validation of traditional treatments against malaria. One species native in South America, , and is largely used against human malaria in Brazil has a prophylactic effect, interfering with the viability of sporozoites in and experiments.
疟疾是一种地方病,2019年有2.29亿人感染,40.9万人死亡。由于尚无有效的商业疫苗来预防该疾病,疾病控制基于早期诊断和使用抗疟药物进行特异性治疗。药物化疗在历史上与各种文化中使用传统植物浸剂和其他天然产物密切相关。基于此类知识的研究已在医学上产生了两种药物:来自南美洲亚马逊高地雨林原生的金鸡纳属植物的生物碱奎宁,以及来自千年中医药中的青蒿的青蒿素。青蒿素联合疗法(ACTs)被证明对疟原虫高度有效,被视为“对抗耐药疟原虫的最后手段”,但由于多药耐药性的出现,目前使用受限。此外,治疗选择有限使得开发新的抗疟药物变得紧迫。本综述聚焦于通过使用PubMed数据库,以“抗疟药”“植物”和“天然产物”为关键词搜索获得的90种植物的抗疟活性。我们仅选择了过去10年(2011 - 2020年)发表的论文,并进一步分析了那些在感染疟疾的小鼠中进行实验测试的论文。研究的大多数植物物种来自非洲大陆,其次是亚洲和南美洲;它们的抗疟活性是针对无性血液寄生虫进行评估的,只有一个物种被评估了传播阻断活性。从这些植物中分离出的只有少数化合物具有活性且其作用机制已被阐明,从而限制了这些药用植物作为新型抗疟药效基团来源的贡献,而新型抗疟药效基团对于开发有效药物是非常必要的。尽管如此,寻找生物活性化合物仍然是开发新抗疟药以及验证传统疟疾治疗方法的一种有前景的策略。一种原产于南美洲且在巴西大量用于治疗人类疟疾的植物具有预防作用,在[具体实验名称1]和[具体实验名称2]实验中干扰子孢子的活力。